Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Clinical trial NCT06035224 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06035224
- Sponsor
- RenJi Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-23
- Primary completion
- 2026-01-12
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.